EMA Authorised: Naglazyme (galsulfase) — BioMarin International Limited

View source ↗

Summary

The European Medicines Agency authorised Naglazyme (galsulfase) by BioMarin International Limited for treating mucopolysaccharidosis type VI in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis Type Vi

Drugs mentioned

• NAGLAZYME (GALSULFASE)

Snippet

Status: Authorised. Therapeutic area: Mucopolysaccharidosis VI. MAH: BioMarin International Limited. Decision date: 12/12/2024